TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria

Summary

The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond up-to-seven criteria.

Timeline

Start

2023-06-01

Primary completion

2025-05-31

Completion

2025-07-01

Drugs

Indications